Additional file 9 of Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial

Additional file 9: Fig. S9. Impact of MDDCT on the level of IFN- �� in plasma. The Fig. shows the level of IFN-�� in individuals receiving the personalized dendritic-cell therapy (DCT), alone (G5, in black) or following the conditioning regimen consisting of auranofin + nicotinamide (G6, in blue). IFN-gamma was measured by ELISA testing, and data were analyzed by two-way ANOVA. The P-value reported refers to the interaction between time and the previous conditioning regimen.